TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: attachment loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: BOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: dental caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: erosive tooth wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Immunological activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postreperfusion syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical Outcomes Survey Short-Form-36 (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Activity Limitation and Participation Restriction
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in levels of cancer-related fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Concordance between mfERG and En-face OCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite Endpoint of Death
Endpoint domain: Mortality/survival
Primary endpoint: Periprocedural Myonecrosis (PPM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urgent Target Vessel Revascularization (uTVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DAS28-ESR remission at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes over time in the number of patients maintaining discontinuation (maintenance rate)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Patients With Late Treatment-related Gastrointestinal and Genitourinary Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Prognosis of Acute Fulminant Myocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in muscle tonicity related to seizure activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: 2 Year Progression Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in total BACS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CGI global improvement and severity of illness scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Posterior capsule opacification requiring surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Downstaging effect of tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: BMI change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of post operative complications (Clavien-Dindo grade 3-4)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from level of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: number of unexpected hospital deliveries
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction of signs and symptoms associated with allergic conjunctivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematotoxicity Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in HDV RNA quantitative measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in visual acuity (VA) in amblyopic eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length-for-Age Z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diarrhea Prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: One Log Decrease in BCR-ABL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Average Population Spiking Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes Prior to the Booster Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes Prior to the Booster Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Seropositive for Multiple (2, 3 or 4) Dengue Serotypes Prior to the Booster Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in peripheral blood PMNs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of falls reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMG-NCV test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: serum level of IL-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum level of TNF-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum level of hs-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Trough Seated Diastolic Blood Pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in IANR-SCIFRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic profile of TMC435
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitudes of R- and T-waves (and R/T ratios)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in Weight-Normalized Average Daily Parenteral Nutrition IV Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Luteinizing Hormone Pulse Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Six-month Continuous Abstinence From Cigarettes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Aortic dP/dt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacokinetic parameter of ONO-5920/YM529
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Post-testing on the Part/Whole Identity Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Post-testing on the Reading the Mind in the Eyes Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed discrimination threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal PEEP value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decreasing systemic and local side effects of BCG
Endpoint domain: Adverse events/effects
Primary endpoint: Toxicity patterns
Endpoint domain: Adverse events/effects
Primary endpoint: Fall in pulmonary vascular resistance (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response to structured interview
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Efficacy of pomalidomide and low-dose dexamethasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Anterior Knee Pain Scale (AKPS) score to 3 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Numeric Pain Rating Scale (NPRS) score to 3 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of DE-110
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival at 12 and 48 months
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of rare skin cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of patients with hospital discharge at day 7
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Improvement of Dasatinib-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Myocardial T1 relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Manganese uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Negative Postoperative Behavioral Changes
Endpoint domain: Adverse events/effects
Primary endpoint: Discomfort during catheterisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotection Against Vaccine Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprotection Against Pertussis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprotection Against Poliovirus Types 1, 2, and 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical improvement of pouchitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of patients with nocturnal desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of patients with OSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Children's social skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Hypoxic Ventilatory Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forearm Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Quality of Life Scale (QOLS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Hereditary Angioedema (HAE) Attacks Treated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of HAE Attacks With Substantial Relief of the Defining Symptom
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in MATRICS Battery Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants who had a Grade 3 or 4 adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Reactogenicity Signs
Endpoint domain: Adverse events/effects
Primary endpoint: Low Blood Glucose Index (LBGI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemoglobin (Hb) Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Retinal Drusen Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Betamethasone plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change of log transformed urinary albumin to creatinine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent Increase in Sestamibi Retention in the Liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Difference in alcohol consumption
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Relapse
Endpoint domain: Mortality/survival
Primary endpoint: Changes in components of 24-h energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in 24-h substrate oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose (MTD) as assessed by dose limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of pelvic/non-vaginal recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Acceptance of child's diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptance of one's negative experiences
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptance of one's momentary situation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of colored balls correctly identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful transplantation of AML cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of oocytes and mature oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Levels of sleepiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed of processing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Gene expression levels in Duchenne muscular dystrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Feto-maternal outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Time interval of nucleic acid detection becoming negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eligibility rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: serum bactericidal titers against meningococcal serogroups A and C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-PRP antibody concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Linear Deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diet Compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: changes in Parathyroid hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in World Health Organisation Quality of Life Combination
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum Vesical Pressure During Valsalva Manoeuvres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum Abdominal Pressure During Valsalva Manoeuvres
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Detrusor Pressure at Valsalva Manoeuvres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Cytomegalovirus (CMV) Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with sufficient data for analysis of resting heart rate and HRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under plasma concentration-time curve from zero extrapolated to infinity (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under plasma concentration-time curve to time of last measurable concentration (AUC[0-t])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in left ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of weekly episodes of going ≥ 4 waking hours without eating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Children's Yale Brown Obsessive-Compulsive Scale (CY-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Time to Recovery of T4/T1 Ratio to 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants with a Modified Rankin Scale (mRS) score of ≤ 4 Without Decompressive Craniectomy (DC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to phonetic categories
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Appearance of Nasal Passages/Sinuses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women using LNG contraceptive implants at 6 months after delivery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functional subscore of simplified WOMAC Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: false negative rate of PTNB procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grade ≥2 Radiation Pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in pain (PAINAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Behavioral and Psychological Symptoms of Dementia (BPSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total body oxygen consumption (VO2 max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High level of fetuin A in women with PCOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Renal Failure Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Global Response to Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Steady-state peak concentration (Css_max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average steady-state plasma concentration (Css_av)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under steady state plasma concentration-time curve (AUC)ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients showing functional brain changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain intensity and interference
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Muscle Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Presence or absence of a depressive episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutritional status as assessed by standard anthropometric measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of responder patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toxicity of hypofractionated radiation therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative total opioid consumption (oral morphine equivalents)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Visual analog scale (VAS) pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial location of breast tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in overall levels of peripheral inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum levels of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change from baseline in neuropsychological test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: utilization of healthcare resources
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: rates of prescription of AD-specific therapies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in patient activation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma Renin Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Interstitial Cystitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Myofascial Pelvic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Immunologic Deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in PGA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient alive
Endpoint domain: Mortality/survival
Primary endpoint: mean change in HCV RNA level from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight change (Kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acute Change in Minimum Lumen Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes of attention bias score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes